Bitcoin fell to an intraday low of $81,136, down about 2.3% in 24 hours, following renewed US military threat against Iran by President Trump. The Nasdaq Composite dropped 2.6% and the S&P 500 fell 1.2%, pressured by geopolitical risks, rising energy prices, and concerns over AI stock valuations. Treasury yields declined as investors sought safer assets. Market participants now await the Federal Reserve's rate decision scheduled for October 28, which could further influence asset prices.
Bitcoin's recent price drop provides context for cryptocurrency market activity on Pluang as of Oct 24, 2026 01:31 WIB. Among 50 major cryptocurrencies priced on Pluang, 43 rose and 6 fell today. Notable movers include ATOM (Cosmos) at Rp31.868 with a 1-day change of +3.75% and a typical hold time of 61 days, LUNC (Terra Classic) at Rp0,841 with a 1-day change of +3.57% and a typical hold time of 195 days, and YFI (Yearn) at Rp39.837.602 with a 1-day change of +3.00% and a typical hold time of 94 days. Pluang order activity shows mixed buying and selling interest across these assets.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
